https://sirenbiotechnology.com/news-resources/ 2026-10-14T16:50:40+00:00 https://sirenbiotechnology.com/siren-biotechnology-reveals-srn-101-as-lead-asset-for-high-grade-gliomas-with-both-orphan-drug-and-rare-pediatric-disease-designations-from-the-fda/ 2025-01-15T21:31:46+00:00 https://sirenbiotechnology.com/siren-biotechnology-unveils-preclinical-data-for-universal-aav-immuno-gene-therapy-for-cancer/ 2025-01-15T21:31:46+00:00 https://sirenbiotechnology.com/siren-biotechnology-launches-to-pioneer-universal-aav-immuno-gene-therapy-for-cancer/ 2025-01-15T21:31:46+00:00 https://sirenbiotechnology.com/siren-biotechnology-and-catalent-enter-partnership-for-manufacturing-of-aav-gene-therapies-for-cancer/ 2025-01-15T21:31:46+00:00 https://sirenbiotechnology.com/siren-biotechnology-awarded-4m-in-grant-funding-from-the-california-institute-for-regenerative-medicine-cirm/ 2025-01-15T21:31:46+00:00 https://sirenbiotechnology.com/whitelab-genomics-and-siren-biotechnology-announce-strategic-partnership-to-accelerate-ai-powered-advancements-in-gene-therapy/ 2025-01-15T21:31:46+00:00 https://sirenbiotechnology.com/siren-biotechnology-expands-clinical-and-scientific-advisory-board-with-key-industry-leaders/ 2025-03-04T19:12:55+00:00 https://sirenbiotechnology.com/siren-biotechnology-to-present-universal-aav-immuno-gene-therapy-data-at-the-2025-american-society-of-gene-and-cell-therapy-asgct-annual-meeting/ 2025-05-12T20:23:29+00:00 https://sirenbiotechnology.com/siren-biotechnology-to-showcase-clinical-stage-momentum-at-major-2026-healthcare-conferences/ 2026-01-28T12:49:38+00:00 https://sirenbiotechnology.com/siren-biotechnology-announces-fda-clearance-of-first-ind-advancing-company-to-clinical-stage/ 2026-01-28T12:51:20+00:00 https://sirenbiotechnology.com/siren-biotechnology-receives-fda-fast-track-designation-for-srn-101-for-the-treatment-of-recurrent-high-grade-glioma/ 2026-02-23T20:38:24+00:00 https://sirenbiotechnology.com/siren-biotechnology-announces-fda-clearance-of-investigator-initiated-ind-to-advance-phase-1-study-in-recurrent-high-grade-glioma/ 2026-03-23T15:05:34+00:00 https://sirenbiotechnology.com/siren-biotechnology-publishes-foundational-aav-immuno-gene-therapy-data-and-announces-presentations-at-asgct-2026/ 2026-04-25T03:52:32+00:00 https://sirenbiotechnology.com/siren-biotechnology-awarded-8m-in-non-dilutive-grant-funding-from-the-california-institute-for-regenerative-medicine-cirm-to-support-clinical-development-of-srn-101-in-high-grade-glioma/ 2026-06-26T17:06:36+00:00 https://sirenbiotechnology.com/siren-biotechnology-appoints-former-fda-cber-oncology-branch-chief-peter-bross-md-to-clinical-and-scientific-advisory-board/ 2026-10-14T16:50:40+00:00